Tuesday , July 5 2022

NIH grant of $ 4.23 million to support the development of the Research Center in Alzheimer's Disease in Cleveland


The National Institute for Aging of National Institutes of Health (NIH) granted a subsidy of 4.23 million dollars to establish the Research Center on Alzheimer's disease in Cleveland. The two-year award will support the development of a multi-institutional collaboration focused on the acceleration of research for Alzheimer's disease and related dementias.

The Cleveland Alzheimer's disease research center, led by James Leverenz, MD, from Cleveland Clinic, will be one of the 31 centers of excellence in Alzheimer's disease financed by NIH in the country that are part of the program of centers for the search of Alzheimer's diseases. The new multi-institutional center, first in Ohio, brings together leading researchers and clinics at Case Western Reserve University, Cleveland Clinic, Louis Stokes Cleveland, VA Medical Center, MetroHealth System and University Hospitals.

The Alzheimer's Disease Research Centers Program is a national network of researchers and clinics of the leading medical institutions in the United States. Researchers from these centers work to translate the advances of research into an improved diagnosis and the care of people with Alzheimer's disease, as well as find a way to cure and possibly prevent the disease.

More than 5.3 million Americans are suffering from Alzheimer's disease. It is anticipated that this number would almost triple in 2050.

"The Cleveland Alzheimer's Research Center will bring together the considerable experience of medical and academic communities in northeastern Ohio to focus on one of the biggest health crises facing our country and the The state of Ohio, "said Dr. Leverenz, director of the Cleveland Clinic's Lou Ruvo Center for Brain Health in Cleveland. "The center will create a robust infrastructure to streamline research to better understand and treat Alzheimer's disease and related dementias. As a multi-institutional collaboration with a large population of patients and a profound experience in research and treatment of dementia, we are in a unique position to be high – a centralized impact ".

"This is an exciting development for Cleveland and doctors working together from many hospitals can do great things," said Alan Lerner, MD, director of the Center for memory and memory of the brain at the Hospitals University of Cleveland Medical Center. "Our goal is to advance research and, finally, to improve the lives of those affected by this devastating disease."

The new center will support a wide range of studies while educating scientists, health professionals and the public about the causes and treatment of dementia. It will have eight core centers led by experts from the participating institutions: Administrative (Dr. Leverenz), Biomarkers (Lynn Bekris, Ph.D., Cleveland Clinic); Clinic (Dr. Lerner, UH / CWRU); Management of data and statistics (Jonathan Haines, Ph.D., CWRU); Neuropathology (Mark Cohen, M.D. and Brian Appleby, M.D., CWRU / UH); Disclosure, recruitment and commitment (Martha Sajatovic, MD, UH / CWRU), Research Education (Xiongwei Zhu, Ph.D., CWRU) and Translational Therapeutics (Andrew Pieper, MD, Ph.D., Harrington Discovery Institute at UH / VA)).

"Our team is keen to contribute to the new center, providing statistical and computational experience by taking advantage of our extensive experience in the realization of large-scale studies that integrate ocular and clinical data to tens of thousands of lives," he said the Dr. Haines, President of Case. Quantitative Population and Health Sciences Department of Western Reserve. "Alzheimer's disease in all ethnic groups and in all socioeconomic classes is a major burden in northwestern Ohio. Our diversity of urban and rural population, combined with detailed genetic and clinical information and data wealth Additional medical records, this means the new Cleveland center. It is in a unique position to contribute significantly to the national research agenda. "

The specific areas of the center will be atypical Alzheimer's disease (for example, "rapidly progressive"), Lewy's body dementia, healthy people at risk of developing dementia and poorly treated people. In addition to community outreach, the center will develop infrastructures and support for new promising researchers and promote the translation of laboratory results to new therapeutics for these devastating diseases.

Source link